Department of Chemical & Materials Engineering, National Central University, Jhong-Li, Taoyuan 320, Taiwan.
Clinical Research and Imaging Centre, South Australian Health and Medical Research Institute, Adelaide 5001, Australia.
ACS Appl Mater Interfaces. 2024 Jul 17;16(28):36157-36167. doi: 10.1021/acsami.4c06917. Epub 2024 Jul 8.
In situ-forming biocompatible hydrogels have great potential in various medical applications. Here, we introduce a pH-responsive, self-healable, and biocompatible hydrogel for cell scaffolds and the development of a tumor spheroid phantom for magnetic resonance imaging. The hydrogel (pMAD) was synthesized via amino-yne click chemistry between poly(2-methacryloyloxyethyl phosphorylcholine--2-aminoethylmethacrylamide) and dialkyne polyethylene glycol. Rheology analysis, compressive mechanical testing, and gravimetric analysis were employed to investigate the gelation time, mechanical properties, equilibrium swelling, and degradability of pMAD hydrogels. The reversible enamine and imine bond mechanisms leading to the sol-to-gel transition in acidic conditions (pH ≤ 5) were observed. The pMAD hydrogel demonstrated potential as a cellular scaffold, exhibiting high viability and NIH-3T3 fibroblast cell encapsulation under mild conditions (37 °C, pH 7.4). Additionally, the pMAD hydrogel also demonstrated the capability for in vitro magnetic resonance imaging of glioblastoma tumor spheroids based on the chemical exchange saturation transfer effect. Given its advantages, the pMAD hydrogel emerges as a promising material for diverse biomedical applications, including cell carriers, bioimaging, and therapeutic agent delivery.
原位形成的生物相容性水凝胶在各种医学应用中有很大的潜力。在这里,我们介绍了一种 pH 响应、自修复和生物相容的水凝胶,用于细胞支架和磁共振成像的肿瘤球体幻影的开发。该水凝胶(pMAD)是通过聚(2-甲基丙烯酰氧乙基磷酸胆碱-2-氨乙基甲基丙烯酰胺)和二炔聚乙二醇之间的氨基-炔点击化学合成的。流变学分析、压缩力学测试和重量分析用于研究 pMAD 水凝胶的胶凝时间、力学性能、平衡溶胀和降解性。观察到可逆烯胺和亚胺键机制导致在酸性条件(pH ≤ 5)下溶胶到凝胶的转变。pMAD 水凝胶表现出作为细胞支架的潜力,在温和条件(37°C,pH 7.4)下表现出高存活率和 NIH-3T3 成纤维细胞的包封。此外,pMAD 水凝胶还基于化学交换饱和转移效应表现出体外检测脑胶质瘤球体磁共振成像的能力。鉴于其优势,pMAD 水凝胶作为一种有前途的生物医学应用材料,包括细胞载体、生物成像和治疗剂递送。